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Adenovirus early gene 1A (E1A) possesses a potent transcriptional repression function within the first 80 amino acids (E1A 1–80). Our
previous analysis of subdomain 1 (residues 1 to 30) revealed strong correlations between residues required for repression and for disruption of
TBP-TATA complexes. Here, we report a functional analysis of subdomain 2 (48 to 60) by alanine-scanning mutagenesis. 53Ala, 54Pro, 55Glu,
and 56Asp are required for repression in vitro and in vivo and for efficient interaction with p300 but not for disruption of TBP-TATA. These
combined results suggest a model for E1A transcription repression. E1A through subdomains 1 and 2 uses coactivators like p300 as scaffolds to
access E1A repressible promoters. At the promoter, subdomain 1 interacts with TBP to disrupt TBP-TATA and abort transcription initiation. In
further support of this model, we show that E1A 1–80 bound to the p300-binding site retains the ability to interact with TBP.
© 2006 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Ad E1A; Transcription repression; TBP; p300; Mutational analysisIntroduction
Early region 1A (E1A) is the first viral transcription unit
expressed following infection by human adenovirus (Ad). E1A
encodes two multifunctional regulatory oncoproteins of 243-
and 289-amino-acid residues, referred to as 243R and 289R
(Fig. 1A) which interact with a number of cellular transcription
regulatory factors. E1A 243R and 289R are complex multi-
functional proteins whose expression can result in diverse
functions which include transcriptional activation, transcrip-
tional repression, induction of cellular DNA synthesis, cell
immortalization, cell transformation, and interestingly the
inhibition of tumorigenesis and metastasis. E1A 243R shares
the identical amino acid sequence with E1A 289R except for
conserved region 3 (CR3), a 46-amino-acid domain unique to
289R. Using synthetic polypeptides, our laboratory was able to
demonstrate that CR3 is an independent functional domain that
is both essential and sufficient for activation of viral early genes
(Green et al., 1988; Lillie et al., 1987). CR1 (amino acids 40 to
80) and CR2 (amino acids 120 to 139) are common to both⁎ Corresponding author. Fax: +1 314 977 8798.
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doi:10.1016/j.virol.2006.03.041243R and 289R and together with the non-conserved N
terminus (amino acids 1 to 39) are required for the growth
regulatory functions of E1A (Moran, 1993; Moran et al., 1986).
Conserved region 4 (CR4) is localized within a 14-amino-acid
region near the C terminus of exon 2 and possesses an
independent transformation suppression activity (Subramanian
et al., 1989; Boyd et al., 1993).
E1A 243R induces cell cycle progression of quiescent cells
apparently by two pathways (Lillie et al., 1987; Howe et al.,
1990) that may act synergistically (Shenk, 2001). The first and
most studied pathway involves interaction of the retinoblastoma
tumor suppressor protein (pRb) with sequences within CR1 and
CR2. The second pathway leading to cell cycle progression
maps within the E1A N-terminal 80 amino acids (Song et al.,
1995a). Cellular DNA induction, cell immortalization, and
oncogene cooperation have been shown by genetic studies to
require this N-terminal pathway. An interesting biological
function of E1A, the ability to repress transcription from genes
involved in growth regulation, maps to sequences within CR1
and the E1A N-terminus (Boulukos and Ziff, 1993; Hen et al.,
1985; Stein and Ziff, 1987; Webster et al., 1988; Yu et al., 1990).
The multifunctional protein domain structure of E1A
complicates the investigation of a single functional domain in
Fig. 1. (A) A schematic of adenovirus early region 1 (E1A) proteins 289R and 243R. Indicated are the regions conserved amongst Ad serotypes. Below is the sequence
of the 80-amino-acid N-terminal E1A transcription repression domain. Outlined in gray are the two subdomains required for the repression function. In red are the
amino acids within the first subdomain already identified as important for E1A repression. (B) E1A 1–80 and E1A 1–80 single amino acid substitution mutant
polypeptides (1 μg) were resolved by SDS PAGE and stained with SYPRO orange (Molecular Probes). Polypeptide bands were visualized by fluorescence laser
scanning. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
313P.M. Loewenstein et al. / Virology 351 (2006) 312–321the context of the full-length molecule. To investigate the
mechanism of E1A transcription repression, our laboratory
developed in vitro transcription and in vivo cell microinjection
assays to analyze transcriptional repression (Green et al., 1998;
Loewenstein et al., 1998; Song et al., 1995a, 1995b, 1995c,
1997). Using these assays, a recombinant protein containing
only the N-terminal 80 amino acids (E1A 1–80) was found to
strongly repress transcription of E1A-repressible promoters in a
manner that faithfully recapitulates the transcriptional repres-
sion activity of the full-length E1A 243R protein. Briefly, wild-
type E1A 1–80 has the equivalent transcription repression
activity as the full-length E1A 243R molecule in the in vitro
transcription repression assay and in the in vivo cell
microinjection assay (Song et al., 1995a). Further, a series of
deletion mutants constructed within an E1A 1–80 background
(1–80Δ4–25, 1–80Δ26–35, 1–80Δ30–49, 1–80Δ48–60, 1–
80Δ61–69, 1–80Δ70–80) were found to have the same
transcription repression activities in vitro as reported for the
corresponding full-length E1A 243R mutants (Howe et al.,
1990; Song et al., 1995a). Promoters reported to be repressible
in vivo by the expression of E1A 243 are repressed in vitro by
both E1A 1–80 and E1A 243R (human collagenase, rat insulin
II, SV40 early promoter, and the HIV LTR promoter) (Song et
al., 1995a, 1995b). E1A non-repressible promoters such as the
adenovirus major late promoter (MLP), human histone 4
promoter, and the Rous sarcoma virus promoter are resistant
to repression by both E1A 1–80 and E1A 243R proteins in
vitro, attesting to the promoter specificity of repression by E1A
1–80.
The basal transcription factor TBP (TATA-binding protein)
has been strongly implicated as a functional target of E1A
repression (Song et al., 1995a; 1995b, 1995c, 1997; Boyd et al.,
2002). Briefly, repression by E1A 243R and E1A 1–80 in vitro
is reversed by the addition of TFIID or recombinant TBP.
Further, the addition of TBP to an E1A 1–80 affinity-depleted
nuclear extract restores the ability of the extract to supporttranscription. Significantly, E1A 243R as well as E1A 1–80
interferes with TBP-TATA interaction in vitro. This ability of
E1A to disrupt interaction between TBP and the TATA box is
unique among transcriptional repressors that target TBP (Song
et al., 1997).
The multifunctional transcription factor p300 interacts with
E1A through sequences important for the E1A transcription
repression function. p300 and the closely related CREB-binding
protein (CBP) (Chrivia et al., 1993; Eckner et al., 1994) belong
to a conserved family of coactivators recruited to cellular
promoters through interaction with specific transcription factors
or as a complex with other cofactors (Arany et al., 1995;
Chakravarti et al., 1996, 1999; Yang et al., 1996). Genes
coactivated by p300/CBP are potential targets for the E1A
repression function because those genes are often involved in
cell differentiation and for the maintenance of quiescence. E1A
has been reported to possess several biochemical activities,
some of which could be related to the E1A repression function,
including inhibition of PCAF-dependent transcription (Yang et
al., 1996; Puri et al., 1997) and blocking recruitment of RNA
polymerase II on cyclic AMP-dependent promoters (Nakajima
et al., 1997). These findings are of great interest, but it is unclear
to what extent they relate to the E1A transcription repression
function.
To help understand E1A N-terminal activities and their in
vivo significance, a structure–function analysis of E1A single-
amino-acid substitution mutants of the first thirty amino acids of
E1A's N-terminus has been carried out (Boyd et al., 2002). Two
regions of importance within subdomain 1 were found. First,
amino acids 2Arg, 3His, 4Iso, 5Iso, and 6Cys are required for
E1A repression as well as for the ability of E1A to disrupt a
TBP-TATA complex. Second, amino acid 20Leu is essential for
E1A repression and for disruption of a TBP-TATA complex. Of
these critical amino acids, only 6Cys is essential for interaction
with E1A's cellular partners TBP and p300 in an in vitro
binding assay. These studies indicate that both p300 and TBP
314 P.M. Loewenstein et al. / Virology 351 (2006) 312–321are cellular targets for E1A repression and led to a proposed
model that the E1A repression domain uses p300 and/or similar
interacting coactivators as molecular scaffolds to target specific
promoters involved in growth regulation. As described here, to
further explore this hypothesis, we constructed alanine-
scanning single amino acid substitution mutants within the
second domain required for E1A repression, amino acids 48 to
60. The results of functional analysis of these mutants add
further support to a two-step model for E1A transcriptional
repression.
Results
Amino acid residues 53, 54, 55, and 56 within subdomain 2 are
required for in vitro transcription repression
We have cloned, expressed, and characterized a panel of
alanine-scanning mutants covering amino acids 48 to 60, the
second subdomain required for the E1A N-terminal repression
function. These mutants were constructed in an E1A 1–80
amino acid backbone which is sufficient for the E1A
transcription repression function. The scanning mutants were
cloned into the pQE70 expression vector from which C-terminal
6× His tagged polypeptides were expressed. Polypeptides were
purified to near homogeneity (Fig. 1B) and used for in vitro and
in vivo functional studies described below.
First examined was the ability of each E1A 1–80 single
amino acid substitution mutant to repress transcription initiated
in vitro using a well-characterized assay that measures
transcription from the HIV LTR promoter and yields a run-off
transcript of 874 bases (Loewenstein et al., 1998). All mutants
were examined by comparison to wild-type E1A 1–80 at 30 ng,
60 ng, 125 ng, and 250 ng of polypeptide per reaction mixture.
In the absence of E1A 1–80, there is strong transcription from
the HIV LTR (Fig. 2, first reaction, top row). E1A 1–80
polypeptide represses transcription in a dose-dependent manner.
At the lowest concentration, transcription is repressed over
60%, and at the highest concentration, transcription is repressedFig. 2. In vitro transcription reaction reactions showing that E1A amino acid resid
Transcription reactions (25 μl) containing a linearized pHIVLTR template, 8 μl of nuc
mutant polypeptide were performed. E1A 1–80 and the non-defective mutant E1A 1–
LTR promoter (874 bases run-off transcript). Representative titrations of substantiall
E1A 1–80 56Ala are illustrated. Titrations of defective deletion mutants E1A 1–80over 96%, as measured by PhosphorImage analysis. E1A 1–
80Δ4–25, which deletes subdomain 1, does not significantly
repress transcription. E1A 1–80Δ48–60, which deletes sub-
domain 2, is also substantially defective for repression function,
as expected.
Four E1A 1–80 substitution mutants were found to be
substantially defective: 53Ala→Gly, 54Pro→Ala, 55Glu→Ala,
and 56Asp→Ala (Fig. 2, second and third row). The other
single amino acid substitution mutants within residues 48 to 60
were at or near wild-type activity as illustrated by 48Asp→Ala
(Fig. 2, second row). Independent preparations of His tagged
E1A 1–80 53Gly, E1A 1–80 54Ala, E1A 1–80 55Ala, and E1A
1–80 56Ala were examined in the in vitro transcription assay
with essentially the same results, confirming that the deficiency
of the repression function was due to the amino acid substitution
and not to variability in polypeptide preparation. We conclude
that a “cluster” of amino acids between residues 53 and 56 is
important for the E1A transcription repression function in vitro.
The amino acid residues required for in vitro transcription
repression are the same as those required for transcription
in vivo
It is important to establish that mutants identified as
repression defective in the in vitro assay are also defective in
vivo. For this purpose, a cell microinjection repression assay
was employed (Green et al., 1998; Boyd et al., 2002). E1A 1–
80 mutant polypeptides are injected directly into the cell nucleus
and repression of transcription from coinjected SV40 large T
antigen promoter-reporter measured after 4 h by immunofluo-
rescence using monoclonal antibody directed against the SV40
T antigen. This assay has an advantage relative to transient
expression of not being influenced by differences in expression
of mutant polypeptides in transfected cells.
T antigen (red fluorescence) is detected in about 80% of
successfully injected cells that are scored by green fluorescent
protein (GFP) expressed from coinjected pEGFRN-1 (Clon-
tech) (Fig. 3A). Coinjection of E1A 1–80 at 25 ng/μl repressesues 53, 54, 55, and 56 are required for repression by E1A 1–80 polypeptide.
lear extract, and 30 ng, 60 ng, 120 ng, or 250 ng of wild-type E1A 1–80 or E1A
80 48Ala show efficient dose-dependent repression of transcription from the HIV
y defective mutants E1A 1–80 53Gly, E1A 1–80 54Ala, E1A 1–80 55Ala, and
Δ48–60 and E1A 1–80Δ4–25 are also shown.
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3A). However, no significant repression of the SV40 promoter
was observed after coinjection with the repression-defective
mutant E1A 1–80Δ48–60 (Fig. 3A). When E1A 1–80 53Gly,
E1A 1–80 54Ala, E1A 1–80 55Ala, and E1A 1–80 56Ala were
coinjected at 25 ng/μl, their inability to efficiently repress
transcription is apparent (Fig. 3B). The other single amino acidsubstitution mutants within E1A 1–80 residues 48 to 60
exhibited wild-type or near wild-type repression ability as
illustrated by E1A 1–80 48Ala (Fig. 3B).
Quantitative comparison of the E1A 48 to 60 amino acid
requirements for transcription repression in vitro and in vivo
The averages of 3 to 5 independent in vitro transcription
repression analyses are shown in Fig. 4A, and the averages of 3
to 4 cell microinjection analyses are shown in Fig. 4B. In both
analyses, E1A 1–80 53gly, E1A 1–80 54Ala, E1A 1–80 55Ala,
and E1A 1–80 56Ala were substantially defective for
transcription repression function. In the in vivo assay, the
substitution of alanine for 51Val and 52Thr appears to produce a
partially defective phenotype. It is possible that the in vivo
assay is somewhat more stringent in measuring transcription
repression, and that these amino acids are also involved in the
repression function. In any case, it is clear that the core “group”
of residues (53Ala, 54Pro, 55Glu, and 56Asp) is important for
E1A 1–80 transcription repression function both in vitro and in
vivo.
The amino acid residues in subdomain 2 important for E1A
repression are needed to interact with p300 but not to bind TBP
TBP and p300 have been implicated as cellular targets or
partners in E1A repression. To determine whether single amino
acid mutations in subdomain 2 affect the ability of E1A 1–80 to
interact with TBP or the E1A-binding site in p300, protein–
protein-binding assays were performed. Fusion proteins con-
taining (i) GST with full-length TBP (GST-TBP) and (ii) GST
with a p300 fragment containing the E1A-binding site (GST-
p300 segment B′) were immobilized on GSH-agarose and
incubated with wild-type and mutant E1A 1–80 polypeptides.
The input was monitored to ensure that approximately equal
levels of E1A polypeptides were available for binding. E1A 1–
80 polypeptides bound to the GST fusion proteins were
resolved by SDS PAGE, transferred to PVDF membranes,Fig. 3. Transcription repression assay by cell microinjection showing that the
E1A 1–80 mutant polypeptides defective for in vitro repression are also
defective for in vivo repression. Data are collected and tabulated as described in
Materials and methods by direct microscopic examination. Shown are
representative portions of fields of microinjected cells to illustrate the assay.
A549 cells grown on cover slips were comicroinjected with the E1A repressible
SV40 T antigen producing plasmid p1–11, the green fluorescent protein (GFP)
producing plasmid pEGFP-N1, and E1A 1–80 or E1A 1–80 mutant
polypeptide. After 4 h, cells were fixed and stained for T antigen. Successively
injected cells producing GFP were detected by fluorescence microscopy with a
FITC filter. T-antigen-positive cells were visualized using fluorescence
microscopy with a rhodamine filter. (A) Shown are representative fields
illustrating successfully injected cells (GFP) and T antigen producing cells
(SV40 T-Ag). In the absence of E1A polypeptide (No peptide), about 80% of
successfully injected cells produce T antigen. Coinjected E1A 1–80 efficiently
represses transcription from the SV40 T antigen promoter. Coinjected E1A 1–
80Δ48–60 does not significantly repress transcription from the SV40 T antigen
promoter. (B) Representative examples showing that E1A 1–80 substitution
mutants 53Gly, 54Ala, 55Ala, and 56Ala are deficient in transcription repression
function, whereas E1A 1–80, 48Ala retains the ability to repress transcription
from the SV40 T antigen promoter.
Fig. 4. (A) Summary of the in vitro repression activities of the E1A 1–80 substitution mutants relative to wild-type E1A 1–80 at 60 ng per reaction. The data are an
average of four or more assays. The ranges of data are indicated. (B) A summary of in vivo repression activities of the same mutants as shown in panel A. Data are the
average of at least three individual experiments and represent all of the cells that have been successfully microinjected and scored by direct microscopic examination.
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polyclonal antibody raised against the E1A CR1 domain.
Results from a typical binding experiment are presented in Fig.
5A. Wild-type E1A 1–80 bound efficiently to both GST-p300
and GST-TBP (Fig. 5A) but not to GST alone (data not shown).
These interactions are specific since the deletion mutant E1A 1–
80Δ4–25 is substantially defective for binding to both GST-
p300 and GST-TBP (Fig. 5A). This mutant was previously
shown to lack E1A repression activity and to lack the ability to
bind TBP and p300 (Song et al., 1997; Boyd et al., 2002). The
deletion mutant E1A 1–80Δ48–60, which is also defective for
transcription repression function, is also substantially defective
in its ability to bind GST-p300 but is not significantly defectivefor binding GST-TBP. These findings indicate that there is no
binding site for TBP within amino acids 48 to 60. Consistent
with this finding, no single amino acid substitution mutant was
defective in ability to bind TBP (Fig. 5A). In contrast, the single
amino acid substitution mutants E1A 1–80 53Gly, E1A 1–80
54Ala, E1A 1–80 55Ala, and E1A 1–80 56Ala were all
significantly defective for binding GST-p300.
Fig. 5B is a quantitative representation of 3 to 4 in vitro
binding assays for GST-p300 segment B′. E1A 1–80 53Gly,
E1A 1–80 54Ala, E1A 1–80 55Ala, and E1A 1–80 56Ala
exhibited phenotypes that bound p300 less than 40% as
effectively as wild-type E1A 1–80. Mutants with substitution
of Ala for 50Asp, 51Val, and 52Thr also bound p300 less
Fig. 5. (A) A typical in vitro binding experiment. E1A 1–80 and E1A 1–80 mutant polypeptides (Input) were incubated with a protein fragment of p300 containing the
E1A-binding site (GST-p300 segment B′) or with TBP (GST-TBP) as described in Materials and methods. Bound E1A 1–80 polypeptides were eluted, resolved by
SDS PAGE, and visualized by immunoblot. (B) Summary of binding experiments measuring the ability of E1A 1–80 mutants to bind a protein fragment of p300
containing the E1A-binding site relative to wild-type E1A 1–80. (C) Summary of experiments measuring the ability of the same E1A mutants to bind TBP relative to
wild type E1A 1–80. The data from panels B and C are the averages of 3 to 4 independent experiments.
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contiguous residues may also be involved in the interaction with
p300. However, it is clear that 53Gly, 54Ala, 55Ala, and 56Ala,
the “core” residues defective for transcription repression, are the
most defective residues for p300 binding. Fig. 5C is aquantitative representation of three independent assays for the
interaction of the single substitution mutants with GST-TBP. No
single residue between 48 and 60 could be identified as
important for interaction with GST-TBP. Further, E1A 1–
80Δ48–60 exhibits a phenotype that is not substantially
Fig. 6. (A) A schematic of the TBP recruitment assay. (B) Immunoblot analysis
for E1A 1–80 bound to GST agarose or GST-p300-seqment B′ agarose after
preincubation with various amounts of E1A 1–80 followed by incubation with
hTBP. (C) Immunoblot analysis for TBP in the same samples as described above
(B).
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amino acids in this region are important for the repression
function and for interaction with p300 they are dispensable for
interaction with TBP.
In vitro recruitment of TBP to a p300 E1A 1–80 complex
To determine whether the E1A repression domain can
interact with both p300 and TBP in a manner that could beFig. 7. Electrophoretic mobility shift analysis (EMSA) showing that residues within th
GST-TBP was incubated with a radiolabeled TATA consensus oligonucleotide in the
strong gel shift is detected. E1A 1–80 disrupts the TBP/TATA complex in a dose-dep
loses the ability to disrupt a TATA/TBP gel shift. By contrast, E1A 1–80Δ48–60, wfunctionally significant, we asked if E1A 1–80 could recruit
TBP to a p300/E1A 1–80 complex. Fig. 6A shows a schematic
of an in vitro binding assay that tests these interactions. Briefly,
GSTagarose or GST-p300 segment B′ agarose is incubated with
an 0.5- to 20-fold molar excess of E1A 1–80 polypeptide. After
removing unbound E1A 1–80, the resin is incubated with about
a two fold molar excess of TBP. After removal of unbound TBP,
bound proteins are eluted, resolved by SDS PAGE, and
subjected to immunoblot analysis. Shown in Fig. 6B are
samples probed with antibody against E1A and shown in Fig.
6C are aliquots of the same samples probed with antibody
against TBP. Lanes 1 and 2 are from GST agarose incubated
with 0. 5× and 20× molar excess of E1A 1–80. Neither bound
detectable amounts of E1A 1–80 or TBP. Lane 3 is GST-p300
segment B′ agarose that was not preincubated with E1A 1–80
polypeptide and then incubated with TBP. No detectable TBP
bound directly to GST-p300 segment B′. Samples shown in
lanes 4 through 8 were preincubated with increasing amounts of
E1A 1–80 and then challenged with TBP. Increasing amounts
of bound E1A 1–80 were detected in the eluted samples, and
importantly, increasing amounts of TBP were also found in
these samples. These findings demonstrate that TBP can interact
in a dose-dependent manner with the E1A N-terminus bound as
a complex with the E1A-binding domain of p300.
Residues within the E1A 1–80 subdomain 2 are not needed to
disrupt interaction between TBP and the TATA box
We have previously shown that the E1A 243R protein and
the E1A 1–80 polypeptide can disrupt interaction between TBP
and TATA box DNA, as shown by both DNase footprint
analysis and EMSA (gel shift analysis) (Song et al., 1997; Boyd
et al., 2002). This ability implies an in vivo function for the E1A
repression domain. It was therefore important to examine the
E1A 1–80 mutant polypeptides for ability to interfere with
TBP-TATA interaction. An end-labeled oligonucleotide probe
containing a TATA element was incubated with recombinant
TBP in the absence or presence of wild-type E1A 1–80 or
mutant E1A 1–80 polypeptide. TBP-TATA complexes were
resolved by gel electrophoresis on a low percentage acrylamide
gel and visualized by PhosphorImage analysis. As shown in
Fig. 7, when TBP is incubated in a reaction mixture containing
the consensus TATA element oligonucleotide, a shifted band
containing the TBP-TATA complex is formed. Addition of wild-
type E1A 1–80 polypeptide disrupts the formation of the TBP-
TATA complex in a dose-dependent manner (30 ng, 60 ng, ande E1A 1–80 subdomain 2 are dispensable for disruption of a TATA-TBP complex.
presence or absence of E1A 1–80 polypeptides. In the presence of GST-TBP, a
endent manner, whereas E1A 1–80Δ4–25 which lacks E1A 1–80 subdomain 1
hich lacks subdomain 2, retains the ability to disrupt a TATA/TBP gel shift.
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clearly exhibits a wild-type phenotype in that it is able to disrupt
the TBP-TATA interaction in a dose-dependent manner.
However, E1A 1–80Δ4–25, the deletion mutant lacking
repression subdomain 1, has no effect on TBP-TATA complex
formation, as previously reported (Boyd et al., 2002). Analysis
of single amino acid substitution mutants, both wild type and
defective for transcription repression, found no mutant unable to
disrupt a TBP-TATA complex (data not shown).
Discussion
Reported here are the results of mutational analysis of
subdomain 2 (residues 48–60) of the E1A 1–80 repression
domain. Table 1 summaries the findings from the mutational
analysis of both subdomains needed for the repression function
of E1A 1–80. As observed for subdomain 1 (Boyd et al., 2002),
there is good agreement among the amino acids critical for the
repression function in vitro and in vivo. Residues 53Ala, 54Pro,
55Glu, and 56Asp are important for function because when
these residues are substituted with alanine (glycine for 53Ala),Table 1
Functional activities of mutants in E1A repression subdomain 1 (amino acids
1 to 30) and subdomain 2 (amino acids 48 to 60) 1
E1A 1–80 mutant
polypeptide
In vitro
repression
In vivo
repression
p300
Binding
TBP
binding
TBP-TATA
disruption
E1A 1–80 +++ +++ +++ +++ +++
E1A 1–80 2Ala + ++ +++ +++ ++
E1A 1–80 3Ala − + +++ +++ ±
E1A 1–80 4Ala − ± +++ +++ −
E1A 1–80 5Ala − ± +++ +++ −
E1A 1–80 6Ala − − − − −
E1A 1–80 7Ala +++ +++ +++ +++ +++
E1A 1–80 8Ala
through E1A
1–80 17 Ala
+++ +++ +++ +++ +++
E1A 1–80 18Ala +++ +++ +++ +++ +++
E1A 1–80 19Ala +++ +++ +++ +++ +++
E1A 1–80 20Ala − ± +++ +++ −
E1A 1–80 21Ala +++ +++ +++ +++ +++
E1A 1–80 22Ala
through E1A
1–80 30Ala
+++ +++ +++ +++ +++
E1A 1–80 48Ala +++ +++ +++ +++ +++
E1A 1–80 49Ala +++ +++ +++ +++ +++
E1A 1–80 50Ala +++ +++ ++ +++ +++
E1A 1–80 51Ala +++ ++ ++ +++ +++
E1A 1–80 52Ala +++ ++ ++ +++ +++
E1A 1–80 53Gly + − ± +++ +++
E1A 1–80 54Ala ± − ± +++ +++
E1A 1–80 55Ala ± − ± +++ +++
E1A 1–80 56Ala ± ± ± ++ +++
E1A 1–80 57Ala +++ +++ +++ +++ +++
E1A 1–80 58Ala +++ +++ +++ +++ +++
E1A 1–80 59Ala +++ +++ +++ +++ +++
E1A 1–80 60Ala +++ +++ +++ +++ +++
E1A 1–80Δ48–60 − − − ++ +++
E1A 1–80Δ4–25 − − − − +++
1 +++Represents 75–100% of wild type activity; ++represents 60–75%;
+represents 40–60%; ±represents 20–40%; and −represents less than 20%.the resultant phenotype is substantially defective for transcrip-
tion repression function. Unlike the defective mutants within
subdomain 1, the mutants defective for transcription repression
retain the ability to disrupt TBP-TATA interaction. Consistent
with this finding, 53Gly, 54Ala, 55Ala, and 56Ala are not
defective for interaction with TBP. These mutants are, however,
significantly deficient for interaction with p300, which may
explain the deficiency of 53Gly, 54Ala, 55Ala, and 56Ala for
transcription repression.
p300 was first identified by its interaction with E1A and
appears to play an important role in the ability of E1A to repress
transcription. But as discussed in the introduction, the nature of
this role is unclear. Of interest in this regard, several amino acid
substitution mutants (in 50Asp, 51Val, and 52Thr-see Fig. 5A)
adjacent to the critical core residues 53Ala, 54Pro, 55Glu, and
56Asp, exhibited reduced affinity for p300. It is possible that
these amino acids are involved in p300 interaction but are not
sufficiently deficient to exhibit a defective repression phenotype
in vitro. It is noted that 50Asp, 51Val, and 52Thr do exhibit
reduced transcription repression ability in vivo.
In previous studies, we identified a component of the basal
transcription machinery, TBP, as a key target of the E1A
repression function. Because p300 appears to be involved in
E1A repression and because p300 functions as a coactivator for
promoters that regulate the cell cycle and cell differentiation, it
is an attractive possibility that promoter-bound p300 serves as a
binding site that E1A utilizes to gain access to specific cellular
promoters involved in growth regulation. These considerations
and the observations from mutational analysis of the two
subdomains within the N-terminal repression domain suggest a
two-step model.
During the first step, E1A uses p300 as a high-affinity
“molecular scaffold” to access specific E1A repressible
promoters. E1A likely binds p300 through 6Cys (and possibly
adjacent amino acids) within the first subdomain and with
53Ala, 54Pro, 55Glu, and 56Asp (and possibly adjacent amino
acids) within the second subdomain. In addition to p300, the
E1A N-terminal repression domain may target other coactiva-
tors as scaffolds, including CBP, PCAF, GCN5, p400, and the
TRRAP chromatin remodeling complex which have been
reported to bind the E1A N-terminus (for review, see Frisch
and Mymryk, 2002).
During the second step, after gaining access to the promoter
through interaction with a “molecular scaffold”, the N-terminal
subdomain of E1A is able to interact with TBP. This
interaction may alter the conformation of TBP, thus melting
it from the TATA box. The in vitro TBP recruitment assay
presented here also supports the two step model of E1A
repression (Fig. 6). The N-terminal repression domain of E1A
appears capable of interacting with both the p300 E1A-
binding domain and with TBP as a complex. The fact that the
E1A N-terminus is capable of dissociating TBP from the
TATA box provides functional significance to these protein–
protein interactions.
The two-step model predicts that (i) E1A can function to
repress promoters containing bound p300, and that (ii) E1A can
be found closely associated with chromatin. Preliminary
320 P.M. Loewenstein et al. / Virology 351 (2006) 312–321evidence for both of these predictions has recently been found
(Green and Loewenstein, manuscript in preparation).
Materials and methods
Plasmids
pHIVLTR Tar+ used in the in vitro repression assay and
pSV40 (p1–11) and pEGFP-N1 used in the in vivo repression
assay were previously described (Boyd et al., 2002). Glutathi-
one S-transferase tagged TBP (GST-TBP) and the E1A-binding
region of p300 (GST-p300 segment B′) were derived from
pGEX vectors (Boyd et al., 2002). phTBP was obtained from
the laboratory of A. Berk.
Construction of plasmids expressing E1A 1–80 mutants
Construction of pQE12-E1A 1–80, pQE12-E1A 1–80Δ4–
25 and pQE12-E1A 1–80Δ48–60 has been described (Song et
al., 1995c). Single amino acid substitution mutants were created
in pQE12-E1A 1–80 using a Gene Tailor Site-Directed
Mutagenesis System kit (Invitrogen). Briefly, the template
pQE12-E1A 1–80 was treated with DNA methylase. PCR
amplification was performed using the circular methylated
template with two partially overlapping primers, both of which
contained the target mutation. The linear double-stranded DNA
product was transformed into DH5α-T1 bacterial cells in which
the PCR product was circularized and the methylated template
digested by endogenous McrBC endonuclease. Colonies
remaining after antibiotic selection contained only unmethy-
lated, mutated plasmid. In this manner, each amino acid in E1A
1–80 between residues 48 to 60 was, in turn, substituted with
alanine except for 53Ala which was substituted with glycine.
The sequence of each E1A 1–80 mutant was confirmed by
DNA sequence analysis. After site-directed mutagenesis, the
E1A 1–80 mutants were transferred from pQE12 into pQE70
(Qiagen) by PCR cloning. Each E1A 1–80 sequence was
reconfirmed by DNA sequence analysis and transfected into
M15/pRep4 bacterial cells (Qiagen).
His-tagged E1A 1–80 polypeptides, His-tagged hTBP, and GST
fusion proteins
E1A 1–80 polypeptides were prepared by a protocol
described previously in detail (Boyd et al., 2002). To prepare
biologically active E1A 1–80 polypeptides, it is important to
remove guanidine-HCl slowly as described (Boyd et al., 2002).
GST-TBP and a fusion of GST and the E1A-binding site
containing B fragment of p300 (GST-p300 segment B′) were
purified as described (Boyd et al., 2002). hTBP was prepared
essentially as described in Bryant et al. (1996).
In vitro transcription repression assay
Preparation of nuclear transcription extracts and in vitro
transcription repression assays were performed as described
previously (Loewenstein et al., 1998; Boyd et al., 2002).Cell microinjection assay for transcription repression
Cell microinjection was performed by coinjection of E1A 1–
80 mutant polypeptides with the E1A repressible promoter p1–
11 which expresses the SV40 T antigen, essentially as described
previously (Green et al., 1998; Boyd et al., 2002). Briefly, A549
cells grown on cover slips were comicroinjected in the nucleus
with p1–11 (8 ng/μl), the green fluorescent protein (GFP)
producing plasmid pEGFP-N1 (10 ng/μl), and E1A 1–80 or
E1A 1–80 mutant polypeptide (25 ng/μl). The level of p1–11
was titered so that ∼80% of successfully injected cells produce
detectable T antigen by 4 h after injection. After fixation and
permeabilization, cells were stained with mouse primary
antibody against SV40 T antigen and with Texas Red
conjugated goat anti-mouse secondary antibody. Successively
injected cells produce GFP and were identified by fluorescence
microscopy with a FITC filter. Successfully injected cells were
scored for the production of T antigen by microscopic
examination using fluorescence microscopy with a rhodamine
filter. The data summarized in Fig. 4B represent the average of
at least 3 independent experiments in which approximately 100
cells were injected for each E1A polypeptide.
Protein-binding assay
GST-linked agarose beads estimated to contain 150 ng of the
GST-ligand (p300 E1A-binding site segment B′ or TBP) were
preincubated for 1 h at 4 °C with 500 μl of NP-40 buffer
(40 mM HEPES pH 7.5, 150 mM KCl, 0. 5 mM EDTA, 1 mM
DTT, 1 mM PMFS, 0.2% NP-40 supplemented with 0. 5 mg/ml
of protein extract (sonicated and clarified M15/pRep4 bacterial
cells). Preincubated beads were recovered by centrifugation at
250 × g for 1 min and resuspended in NP-40-binding buffer
containing 75 ng of E1A 1–80 or E1A 1–80 mutant polypeptide
(∼2- to 3-fold molar excess). E1A 1–80 or E1A 1–80 mutant
polypeptides were incubated with the GST-ligand beads for 1 h
at 4 °C, and the beads were then recovered by centrifugation as
before. Beads were washed in NP-40 buffer (without bacterial
extract) supplemented with KCl to a final concentration of
250 mM. Bound proteins were eluted in SDS sample buffer,
resolved by SDS PAGE on 12% polyacrylamide gels,
transferred to PVDF membranes, and subjected to immunoblot
analysis with affinity purified rabbit antibody directed against a
CR1 peptide (E1A residues 40–80). Following incubation with
secondary antibody (alkaline phosphatase linked mouse anti-
rabbit antibody), the blots were treated with ECF reagent
(Pharmacia-Amersham Biotech) and E1A 1–80 polypeptides
quantitated by fluorescence laser scanning on a STORM 840
Phosphor-Imager using ImageQuant software (Molecular
Dynamics).
TBP recruitment assay
GST and GST-p300 segment B′ calculated to contain 166 ng
of ligand were preincubated as above in NP-40 buffer
containing bacterial extract. After washing twice with NP-40
buffer without bacterial extract the beads were incubated at 4 °C
321P.M. Loewenstein et al. / Virology 351 (2006) 312–321for 2 h in NP-40 buffer containing either no E1A 1–80 peptide
or 1:0.5, 1:1, 1:2, 1:5, or 1:20 molar ratios of E1A 1–80. After
washing the beads three times in NP-40 buffer, 350 ng (about a
2-fold molar excess) of hTBP was incubated with each resin
aliquot overnight at 4 °C in NP-40 buffer. Beads were washed
three times in NP-40 buffer, and bound proteins were eluted in
SDS sample buffer, resolved by SDS PAGE on 4–12%
polyacrylamide gels, transferred to nitrocellulose membranes,
and subjected to immunoblot analysis with affinity purified
rabbit antibody directed against hTBP or to E1A. Following
incubation with secondary antibody (horseradish peroxidase
linked goat anti-rabbit), the blots were treated with a sensitive
ECL reagent (SuperSignal West Femto Maximum Sensitivity
Substrate; Pierce) and exposed to film.
Electrophoretic mobility shift analysis (EMSA)
GST-TBP was obtained from Santa Cruz. TFIID consensus
oligonucleotide (Santa Cruz) was end-labeled with [32P] γ-ATP
using polynucleotide kinase. Gel shift reactions were performed
essentially as described previously (Boyd et al., 2002; Bryant et
al., 1996; Tang et al., 1996).
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